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The gut microbiota has emerged as an integral factor that impacts host metabolism and has been suggested
to play a vital role in metabolic diseases such as obesity, insulin resistance, type 2 diabetes, and cardiovas-
cular disease. In humans, cross-sectional studies have identified microbiota profiles associated with meta-
bolic diseases, whereas causationmainly has been demonstrated in animal models. Recent studies involving
microbiota-based interventions in humans, or transfer of disease-associatedmicrobiota into germ-freemice,
underscore that an altered microbiota may directly modulate host metabolism in humans. However, it will be
essential to determine whether an altered gut microbiota precedes development of insulin resistance and
diabetes and to identify the underlying molecular mechanisms. Increased mechanistic insights of how the
microbiota modulates metabolic disease in humans may pave the way for identification of innovative micro-
biota-based diagnostics and/or therapeutics.Introduction
The adult gut microbiota consists of up to 100 trillion microor-
ganisms, equivalent to ten times our total number of somatic
and germ cells (Ba¨ckhed et al., 2005). The collective genomes
of our gut microbes (microbiome) may contain >150 times
more genes than our own genome (Qin et al., 2010) and endow
us with physiologic capacities we have not had to evolve on
our own. Thus, it seems appropriate to view ourselves as a
composite of many species and our genetic landscape as an
amalgam of genes between our H. sapiens genome and the mi-
crobiome. Accordingly, the microbiome defines who we are (epi)
genetically and metabolically.
The gut microbiota is altered in obesity (Ley et al., 2005), and
recent studies indicate that the gut microbiota can be consid-
ered an environmental factor that promotes adiposity and
contributes to obesity (Ba¨ckhed et al., 2004, 2007). The gut
metagenomes of obese mice and humans are characterized by
an enrichment of genes involved in carbohydrate metabolism,
and transplantation of an ‘‘obese’’ microbiota into germ-free
mice results in significantly increased adiposity compared with
transplantation of a ‘‘lean’’ microbiota (Ridaura et al., 2013; Turn-
baugh et al., 2006). Thus, it is becoming increasingly clear that
the gut microbiota should be considered an environmental factor
that modulates host metabolism and may contribute to meta-
bolic diseases.
The Gut Microbiota Is Altered in Type 2 Diabetes
The decreased adiposity in germ-free mice is associated with
improved insulin sensitivity and glucose tolerance (Ba¨ckhed
et al., 2004, 2007; Caesar et al., 2012; Rabot et al., 2010), indi-
cating that the gut microbiota directly may contribute to altered
glucose metabolism. Accordingly, several studies based both
on shotgun metagenomics and 16S RNA enumerations provide
evidence that the gut microbiota is altered in prediabetes/meta-
bolic syndrome (Le Chatelier et al., 2013) as well as in type 2 dia-
betes (T2D) (Karlsson et al., 2013; Larsen et al., 2010; Qin et al.,2012). The Karlsson et al. (2013) and Qin et al. (2012) studies
were based on cohorts from Europe and China, respectively,
but despite differences in ethnicities and diet, both observed
that subjects with T2D had a lower proportion of butyrate-pro-
ducing Clostridiales (Roseburia and Faecalibacterium prausnitzii)
and greater proportions of Clostridiales that did not produce
butyrate. Despite similar changes in the metagenome and buty-
rate-producing bacteria, the bacterial taxa were markedly
different in the two cohorts, demonstrating that the gut micro-
biota is dramatically impacted by diet and ethnicity.
Previous studies have demonstrated increased levels of E. coli
and Proteobacteria in the fecal microbiota of subjects with
T2D, but no information about medication was provided in
these reports (Larsen et al., 2010; Qin et al., 2012).We recently
demonstrated that subjects with T2D who used metformin
had increased levels of Enterobacteriaceae (i.e., Escherichia,
Shigella, Klebsiella, and Salmonella) and decreased levels of
Clostridium and Eubacterium compared with those that did not
take metformin (Karlsson et al., 2013). Thus the ‘‘true’’ T2D pro-
file may be masked by metformin or other drugs. For example,
metformin increase the levels of Akkermansia muciniphila, a
mucus-degrading, short-chain fatty acids (SCFAs)-producing
bacteria, in the gut (Shin et al., 2014). Interestingly, oral adminis-
tration of A. muciniphila protects against obesity and enhances
glucose tolerance in mice (Everard et al., 2013; Shin et al.,
2014). These findings not only further highlight the importance
of medication monitoring but also highlight the possibility that
some drugs may act by modulating the microbiota (Figure 1).
It would be clinically relevant to identify individuals who will
develop T2D in order to start with preventive strategies early.
Based on the metagenomic data, we developed a model that
separated T2D subjects from healthy controls with a predictive
power that was far better than that of body mass index (Karlsson
et al., 2013). Since these analyses were based on sequenced
taxa andmost taxa have not yet been sequenced, we developed
a refined strategy based on the assumption that genes from theCell Metabolism 20, November 4, 2014 ª2014 Elsevier Inc. 753
Figure 1. Interaction between Gut Microbiota and Host Insulin Sensitivity
Carbohydrate and proteins are themajor components of undigested food available for gutmicrobial fermentation in the colon. SCFAs and colonic gases (H2, CO2,
and CH4) are the major products of carbohydrate fermentation. Amino acid fermentation leads to the production of BCFAs, SCFAs, ammonia (NH3), amines
(-NH2), hydrogen sulfide (H2S), phenol, and phenolic derivatives (indole and p-cresol). During fasting states, host mucus can be degraded by mucus-degrading
bacteria (e.g., Akkermansia sp) and serves as essential substrate for gut microbial fermentations. Vitamin production by gut microbes may impact insulin
sensitivity (IS). Drugs, such as metformin and acetaminophen, potentially modulate gut microbiota or their metabolic profiles, thus affecting IS directly or indi-
rectly. The microbial/physiological degradation of Gram-negative bacteria contribute to the systematic increase of LPS that impairs IS. Grey lines represent
microbial-derived metabolites having positive impact on IS, whereas orange lines indicate metabolites leading to a decrease IS.
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ject. We defined such potential new taxa as metegenomic clus-
ters (MGCs), and by basing themodel onMGCs,we could further
improve the discriminatory power of the model (Karlsson et al.,
2013). The MGCs that contributed to the increased discrimina-
tory power were mainly Clostridia that were enriched in healthy
subjects. These findings suggest that it may be possible to
develop novel diagnostic approaches based on analysis of the
gut metagenome. However, prospective well-controlled studies
are needed.
Modulating the Microbiota in Humans Affects
Insulin Sensitivity
The precise role of intestinal microbiota in human metabolism
and insulin resistance remains to be elucidated, but some evi-
dence for direct involvement on insulin sensitivity has recently
emerged. Fecal transplantation provides a unique opportunity
to change an individual’s (small) intestinal microbiota. Infusion
of donor feces was recently demonstrated to be a significantly
more effective treatment for recurrent Clostridium difficile infec-
tion compared with vancomycin (van Nood et al., 2013). Using
a similar strategy, we performed a double-blind randomized
controlled trial to investigate whether a lean microbiota would754 Cell Metabolism 20, November 4, 2014 ª2014 Elsevier Inc.improve glucose homeostasis and lipid metabolism in naive
males with metabolic syndrome (Vrieze et al., 2012). Compared
with subjects that received their own feces (controls), subjects
that received lean donor microbiota improved their insulin sensi-
tivity 6 weeks after the infusion. However, the effect declined in
all subjects over time. Interestingly, not all recipients responded
similarly, which suggests that either some recipients are more
prone to respond or that certain donors function as ‘‘superdo-
nors.’’ At present, the effect appears to be donor rather than
recipient dependent, as the same donor had similar beneficial
effects in two recipients (Vrieze et al., 2012). The improved insulin
sensitivity appeared to be primarily driven by improved periph-
eral muscle insulin sensitivity, as the liver insulin resistance
showed only trend toward improvement. The underlying mecha-
nism for this improvement is currently unknown, but butyrate-
producing bacterial strains were significantly increased in both
small intestinal biopsies and fecal samples of metabolic syn-
drome patients treated with lean donor feces (Vrieze et al.,
2012). However, the exact nature of this symbiotic relationship
remains to be elucidated and whether specific bacterial strains
or their metabolites mediate these beneficial responses.
A 1-week treatment with vancomycin in obese males with
metabolic syndrome reduced peripheral insulin sensitivity
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such as F. prausnitzii, and the treatment reduced the abundance
of Firmicutes and overall intestinal microbiota diversity, which
further supports the importance of butyrate-producing bacteria
as beneficial for improving insulin sensitivity. No effect was
observed with amoxicillin, which targets Gram-negative anaer-
obes. The beneficial effects on metabolism by Gram-positive
bacteria were also demonstrated in a retrospective study where
vancomycin treatment led to an increase in BMI in patients
with infective endocarditis (Thuny et al., 2010). In contrast, sub-
therapeutic doses of antibiotics increase the abundance of bac-
teria that produce butyrate and other SCFAs, which correlates
with increased adiposity in mice (Cho et al., 2012). This strategy
has been exploited for decades by the farm industry to increase
meat production. However, antibiotic usage in society may thus
contribute to changes in the microbiome, which may contribute
to development of T2D.
In addition to producing SCFAs, members of Firmicutes have
a major impact on bile acid metabolism. Accordingly vanco-
mycin treatment reduced the levels secondary bile acids and
increased levels of primary bile acids (Vrieze et al., 2014). The
levels of deoxycholic acid and lithocholic acid, which are efficient
activators of TGR5 signaling, were dramatically reduced. TGR5
mediates improved glucose metabolism and protects against
diet-induced obesity in humans by activating energy expendi-
ture and promoting glucagon-like peptide 1 (GLP-1) secretion
(Thomas et al., 2009; Watanabe et al., 2006). Thus, it appears
as increased levels of butyrate-producing and bile-acid-metab-
olizing bacteria are associated with improved glucose meta-
bolism in humans and may thus constitute novel therapeutic
strategies for treating metabolic diseases.
Does the Gut Microbiota Contribute to Positive Effects
following Bariatric Surgery?
Bariatric surgery is currently the most effective treatment of
severe obesity and induces both dramatic and sustained weight
loss, improvement of insulin sensitivity and T2D, as well as
reduced overall mortality (Carlsson et al., 2012; Sjo¨stro¨m et al.,
2007). The most common bariatric procedure is Roux-en-Y
gastric bypass (RYGB) where the stomach size is dramatically
reduced and empty nutrients directly into the lower small intes-
tine. RYGB results in rapid, dramatic improvement of glucose
metabolism even before weight reduction (Rubino et al., 2004).
Interestingly, another type of bariatric surgery, vertical sleeve
gastrectomy (VSG), where approximately 80% of the stomach
is removed along the greater curvature results in similar meta-
bolic improvements as RYGB, despite the different procedure.
Importantly the efficacy of VSG is comparable to the more com-
plex RYGB (Chambers et al., 2011; Karamanakos et al., 2008).
The altered gut physiology following RYGB contributes to
alteredmicrobial ecology in mice, rats, and humans is character-
ized with increases in Proteobacteria such as Escherichia and
Enterobacter (Furet et al., 2010; Kong et al., 2013; Li et al.,
2011; Liou et al., 2013; Ryan et al., 2014). RYGB had a pro-
nounced effect on the gut microbiota within the first week
following surgery and stabilized after 5 weeks in mice (Liou
et al., 2013), suggesting that the altered gut microbiota may
contribute to the improved host metabolism. Using fecal micro-
biota transplants, the authors could demonstrate that the alteredgut microbiota directly contributed to reduced weight gain (Liou
et al., 2013). However, the mechanism remains so far unknown
but have been associated with Bile flow alteration, Reduction
of gastric size, Anatomical gut rearrangement and altered flow
of nutrients, Vagal manipulation, and subsequent Enteric gut
hormone modulation (BRAVE effects) (Ashrafian et al., 2011).
GLP-1 and bilemetabolism are stronglymodulated by themicro-
biota and may as such contribute to the improved metabolism
following bariatric surgery (Sayin et al., 2013; Wichmann et al.,
2013). For example, the gut microbiota induces signaling
through the nuclear receptor FXR by metabolizing a naturally
occurring FXR antagonist, taurobetamuricholic acid (Sayin
et al., 2013). FXR was recently found to be required for the bene-
ficial effects following bariatric surgery (Ryan et al., 2014), and as
such, bariatric surgery may promote the beneficial metabolic ef-
fects by altering the gut microbiota and by inducing FXR
signaling.
Mechanisms Underlying Microbial Effects of Insulin
Sensitivity
Metabolic Inflammation
The gut microbiota can modulate host metabolism directly or via
interactions with dietary components (Tremaroli and Ba¨ckhed,
2012). Patients with T2D presented increased levels of Escheri-
chia coli (Furet et al., 2010; Qin et al., 2012), which is a Gam-
negative bacteria containing large amounts of lipopolysaccha-
ride (LPS) that induces endotoxemia. Elevated plasma levels of
LPS have been detected in subjects with T2D (Creely et al.,
2007), and administration of LPS tomice for 4 weeks through os-
motic minipumps promoted adipose tissue inflammation and
reduced insulin sensitivity (Figure 1) (Cani et al., 2007). This indi-
cates that microbial-derived proinflammatory molecules may
have direct effects on insulin sensitivity. In contrast, subjects
with T2D have reduced amounts of F. prausnitzii and Roseburia
sp, which are important butyrate-producing microbes (Furet
et al., 2010; Karlsson et al., 2013; Qin et al., 2012) and are
thought to protect against bacterial translocation either directly
or through their ability to produce butyrate (Hansen et al., 2010).
Adipose inflammation and impaired glucose metabolism is
associated with increased macrophage accumulation in the
adipose tissue. We identified a direct role for the gut microbiota
to promote adipose inflammation and found that germ-free mice
have reduced accumulation of macrophages in the adipose tis-
sue and improved glucose homeostasis compared with conven-
tionally raised counterparts (Caesar et al., 2012). Adipose tissue
inflammation and reduced insulin sensitivity is not only charac-
terized by increased macrophage infiltration but also increased
recruitment of T cells (Nishimura et al., 2009; Winer et al.,
2009) and mast cells (Liu et al., 2009), as well as decreased
numbers of regulatory T cells (Feuerer et al., 2009). However,
the precise interactions between the gut microbiota and specific
immune cell subsets in adipose inflammation need to be clari-
fied.
Microbial structural components, such as LPS, are potent ac-
tivators of the innate immune signaling pathways via pattern
recognition receptors. Deletion of such receptors is in general
associated with improved metabolism (Amar et al., 2011a;
Cani et al., 2007; Johnson et al., 2004). However, disrupted
TLR5 signaling has been associated with altered gut microbialCell Metabolism 20, November 4, 2014 ª2014 Elsevier Inc. 755
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evidence also suggests a link between inflammasomes, gut mi-
crobiota, and host metabolism. Mice lacking the inflammasome
complexes NLRP3 or NLRP6 exhibited an altered gut microbiota
and nonalcoholic fatty liver disease (NAFLD) and nonalcoholic
steatohepatitis (NASH) (Henao-Mejia et al., 2012). Importantly,
it was demonstrated that the NAFLD/NASH phenotypes were
directly caused by an altered gut microbiota and driven by
increased influx of TLR4 and TLR9 ligands, presumably LPS
and bacterial DNA, respectively, to the liver where they pro-
moted steatosis through a TLR-dependent mechanism (He-
nao-Mejia et al., 2012). A commonality in many of these models
is that they are associated with altered gut permeability. How-
ever, pathophysiological mechanisms behind intestinal micro-
biota modulation of gut permeability to promote metabolic
disease are currently unknown, but evidence now accumulates
to suggest that T2D can be linked with increased infiltration of
microbes into the peripheral tissues, which may contribute to
the pathogenesis of disease (Amar et al., 2011b). It will also be
important to decipher whether the immune receptors affect
host metabolism through modulation of the microbiota or
through signaling in tissues induced by microbial molecules in
the circulation.
Microbial Metabolites following Interactions with
the Diet
The gut microbiota has profound effects on metabolism of
several dietary components and produces numerous metabo-
lites that can be detected in the circulation (Martin et al., 2007;
Velagapudi et al., 2010; Wikoff et al., 2009). One of the most
widely studied classes is SCFAs that are produced through mi-
crobial fermentation of complex carbohydrates and proteins,
and it is estimated that 30 g of carbohydrates and 13 g of pro-
teins enters the colon each day (MacFarlane and Cummings,
1991; Wrong, 1987). However, these influxes are strongly
affected by dietary habits, gut microbiota, and intestinal transit
times (Hughes et al., 2000). The SCFAs (acetate, butyrate, and
propionate) are the major end products of carbohydrate fermen-
tation, while branch-chain fatty acids (isobutyrate, isovalerate,
and isocaproate) beside SCFA, ammonia, and amines aremainly
derived from protein metabolism (Figure 1). Furthermore, phenol
and indole metabolites are also derived from the fermentation of
aromatic amino acids (phenylalanine, tyrosine, and tryptophan,
respectively) (Hughes et al., 2000; MacFarlane and Cummings,
1991; Mortensen and Clausen, 1996).
Interestingly, low- or restricted-carbohydrate diets can enrich
Gram-negative Bacteroides sp (Walker et al., 2011) and/or
increased gut permeability, which potentially increases system-
atic bioavailability of LPS contributing to obesity and insulin
resistance. This highlights a strong need for long-term follow-
up dietary interventions with special attention on gut-micro-
bial prospective. Prebiotic supplementation containing xylo-
oligosaccharides alone or with an inulin/xylo-oligosaccharides
decrease plasma LPS levels and reduce circulating proinflam-
matory cytokines (Neyrinck et al., 2011; Neyrinck et al., 2012).
Many studies have showed a positive effect of prebiotic supple-
mentation on beneficial microbes (enrichment of Gram-positive
bacteria) and SCFA profiles, especially butyrate (Gibson and
Roberfroid, 1995; Neyrinck et al., 2011). Beside the well-known
effects of butyrate on colonic health, dietary supplementation756 Cell Metabolism 20, November 4, 2014 ª2014 Elsevier Inc.of butyrate can prevent and treat diet-induced insulin resistance
in mouse models (Gao et al., 2009).
Butyrate is the main energy substrate for the colonic epithe-
lium, and accordingly, the colon of germ-free mice is energy
deprived and associated with reduced mitochondrial respiration
and increased authophagy (Donohoe et al., 2011). The energy-
deprived state can also induce increased expression and secre-
tion of GLP-1 from L cells in the colon (Wichmann et al., 2013).
Interestingly, we found that this increased GLP-1 levels did not
contribute significantly to the improved glucose metabolism
observed in germ-free mice, but rather appeared to modulate
small intestinal transit time to allow more time for nutrient ab-
sorption (Wichmann et al., 2013). However, butyrate and propio-
nate can also suppress inflammation and promote release of
GLP-1 from L cells by signaling through the G-coupled receptors
Gpr41 and Gpr43 (Maslowski et al., 2009; Tolhurst et al., 2012).
Thus, it will be important to clarify how the gut microbiota mod-
ulates GLP-1 production in the small and large intestine.
Butyrate, as well as propionate, can also activate intestinal
gluconeogenesis (IGN), conferring improved metabolic pheno-
type as observed after supplementation of fibers to diet-induced
obese mice (De Vadder et al., 2014). Butyrate and propionate
activate IGN through distinct mechanisms. Butyrate activates
IGN gene expression through a cAMP-dependent mechanism,
whereas propionate activates IGN gene expression via a gut-
brain neural circuit involving the fatty acid receptor GPR43 (De
Vadder et al., 2014). Thus, SCFAs, in particular butyrate, can
have beneficial effects on host metabolism through distinct but
complementary mechanisms. Finally, butyrate may have pro-
found effects on epigenetic regulation of gene expression to
influence susceptibility to T2D as a histone deacetylase inhibitor
(Davie, 2003) and by being metabolized into acetyl-CoA to in-
crease histone acetyl transferase activity (Donohoe et al., 2012).
Assessment of the relative contribution of these mechanisms
may be identified using tissue-specific knockouts. Furthermore,
it will be important to identify which of thesemechanisms that are
involved in humans and may mediate the beneficial effects of
butyrate-producing bacteria.
During the fasting state, mucus-degrading bacteria such as
A. muciniphila increase the local bioavailability of N-Acetylglu-
cosamine, N-acetylgalactosamine, fucose, and galactose from
musucs degradation, thus providing metabolic substrates for
other gut microbes (cross-feeding) (Belzer and de Vos, 2012).
Mucus degradation also releases sulfate into the gut lumen,
which can be exploited as electrons sink by the sulfate-reducing
bacteria yielding hydrogen sulfide (Rey et al., 2013). Hydrogen
sulfide has recently gained much attention as gaseous modu-
lator of host physiology and claimed to mediate increased
insulin sensitivity in diabetic rat models (Figure 1) (Xue et al.,
2013). Similarly, methane is one of the least explored fermenta-
tion by-products of gut Archea. A recent study from Mathur
et al. (2014) showed that individuals with higher numbers of
enteric methanogens (methane-producing Archea) may have
impaired glucose tolerance when challenged with a diet rich in
carbohydrates and may also have a higher susceptibility to hy-
perglycemia, independent of basal insulin resistance and BMI.
Thus, different microbiota-derived gaseous modulators may
have a significant impact on host metabolism that still needs
to be explored.
Figure 2. Identification and Personalized Treatments of Patients at Risk for Developing T2D Based on the Microbiota
Subjects may be identified to be at risk to develop T2D based on their microbiome. Different microbiome compositions, together with classical clinical bio-
markers, may potentially allow stratification to different treatments/preventions such as lifestyle interventions (yellow), specific diets and/or prebiotics (red),
classical or novel probiotics (blue), a combination of diet and probiotic (purple), specific drugs (green), or bariatric surgery (blue).
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tation can have important physiological effects on host. For
instance, metabolism of phenolic amino acid to p-cresyl sulfates
was shown to promote chronic kidney-disease-associated insu-
lin resistance (Koppe et al., 2013). The major genera of gut mi-
crobes promoting biotransformation of phenolic compounds
to p-cresyl sulfate include Bacteroides sp, Clostridium sp, and
Fusobacterium sp (Bone et al., 1976; Hughes et al., 2000), which
suggests that diet-microbial interactions may impact the metab-
olome and play important effects on host physiology (Devkota
et al., 2012). Intake of diets rich in tryptophanmay have a positive
impact on insulin sensitivity through microbial metabolism of
tryptophan to the indole-3-propionic acid, which can be a poten-
tial drug target for management of insulin resistance (Figure 1)
(Kuhn et al., 2006).
Gut microbes are also an essential source of vitamins
including folic acid and cobalamin (vitamin B12) (LeBlanc et al.,
2013). Treatment of patients withmetabolic syndromewith these
vitamins reduced insulin resistance and endothelial dysfunction
(Setola et al., 2004). Targeting the specific microbes having a
potential to synthesize these vitamins in vivo could be a novel
approach for management of insulin resistance, and it will be
essential to delineate the relative contribution of different micro-
bial metabolites on insulin sensitivity.
Outlook
The past decade has demonstrated that the gut microbiota is
altered in patients with T2D, which in turn modulates insulin
sensitivity in humans, and that germ-free mice have improved
glucose metabolism. Thus, the microbiota has emerged as an
environmental factor that together with our genetic predisposi-
tion and diet may be considered an important environmental fac-
tor that modulates insulin sensitivity and contributes to T2D.
These findings pave the way for using the gut microbiota todevelop novel diagnostic and therapeutic tools by identifying
specific strains or ‘‘tailor-made’’ bacterial consortium. To this
end, it will be important to move from smaller cross-sectional
studies toward larger prospective studies in order to identify
whether the change in the gutmicrobiota gut-microbial alteration
precedes disease development or the disease state itself cause
such modulations. For instance, increased glycemic load in T2D
may promote the expansion of Lactobacillus sp and Strepto-
coccus sp, reflecting that the disease state may contribute to
this selection. The identification of novel biomarkers need to
be structured around three fundamental questions involving
reproducible measurement, consistent association between
biomarkers, and early detection of otherwise subclinical disease
in epidemiological studies (Morrow et al., 2007). If the early find-
ings that the gut microbiota or relevant microbial biomarker may
predict patients at risk for developing insulin resistance and T2D
can be reproduced, we envision that early identification and
stratification of patients based on the microbiota can be an
important tool for personalized treatments. First subjects with
increased risk of developing insulin resistance or T2D may be
identified based on the microbiome, and thereafter, they may
be stratified to specific therapeutics such as dietary interven-
tions, existing or novel probiotics supplementation, antidiabetic
drugs, or bariatric surgery (Figure 2).
The successful improvement of insulin sensitivity following
fecal transplantation of patients with metabolic syndrome sug-
gests that treatment of T2D in the future may, at least in part,
be based on microbiota interventions. However, since fecal
transplantations are associated with some risks (e.g., transfer-
ring of pathogens), safer and more appealing strategies need
to be developed. In this regard isolation, selection and produc-
tion of novel probiotics raises new challenges, as the major pro-
portion of gut microbiota so far remain uncultured. Furthermore,
the regulatory aspects of such probiotic-based formulationsCell Metabolism 20, November 4, 2014 ª2014 Elsevier Inc. 757
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therapeutics, no formulation development, testing-validation,
or quality control guidelines are available.
Bacteria may also contribute to disease, and recently, a
strain of Enterobacter sp was isolated from an obese individual
(Fei and Zhao, 2013) and fulfills Koch’s postulate. First, the
microorganism must be found in abundance in organisms
suffering from the disease, but should not be found in healthy or-
ganisms. Second, the microorganism must be isolated from a
diseased organism and if possible cultured. Finally, the cultured
microorganism should cause disease when introduced into a
healthy organism and must be reisolated from the inoculated,
diseased host. These kinds of approaches may provide us with
vaccine targets to treat metabolic diseases. In conclusion,
despite the identified (regulatory and logistic) hurdles and chal-
lenges to bring bacterial strains from bench to bedside, there
has been a bloom in biotech companies mining for diagnostic
and therapeutic (probiotic) bacterial strains (Olle, 2013). Thus,
this novel field of research may have a great impact on medicine
in the future, but it will take time to develop validated, safe, and
efficient products.ACKNOWLEDGMENTS
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